Is There a Role for Pentosan Polysulfate in the Prevention of Calcium Oxalate Stones?

Journal of Endourology

Volumn 17, Issue 10, 2003, Pages 855-858

  Jones, Marklyn ^a   Monga, Manoj ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOSAN POLYSULFATE;

CALCIUM OXALATE STONE; CLINICAL TRIAL; CRYSTALLIZATION; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STONE FORMATION; TREATMENT OUTCOME; UROLITHIASIS; UROTHELIUM;

EID: 0346095597     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/089277903772036136     Document Type: Review

References (46)

1. Martin X, Werness PG, Bergert JH, Smith LH. Pentosan polysulfate as an inhibitor of calcium oxalate crystal growth. J Urol 1984;132:786.
2. Senthil D, Malini MM, Varalakshmi P. Sodium pentosan polysulphate: A novel inhibitor of urinary risk factors and enzymes in experimental urolithiatic rats. Renal Fail 1998;20:573.
3. Cao LC, Boevé ER, Schröder FH. The mechanisms of action of glycosaminoglycans (GAGs) in calcium oxalate stone prevention: A review. J Lithotr Stone Dis 1991;3:324.
4. Pantazopoulos D, Karagiannakos P, Sofras F, Kostakopoulos A, Deliveliotis C, Dimopoulos C. Effect of drugs on crystal adhesion to injured urothelium. Urology 1990;36:255.
5. Menon M, Resnick MI. Urinary lithiasis: Etiology, diagnosis, and medical management. In: Walsh PC, Retik AB, Vaughan ED Jr, et al (eds): Campbell's Urology, ed 8. Philadelphia: WB Saunders, 2002, pp 3229-3305.
6. Vermeulen CW, Lyon ES. Mechanism of genesis and growth of calculi. Am J Med 1968;45:684.
7. Jordan WR, Finlayson B, Luxenberg M. Kinetics of early time calcium oxalate nephrolithiasis. Invest Urol 1978;15:465.
8. Hautmann R, Lehmann A, Kumar S. Calcium and oxalate concentrations in human and renal tissue: The key to pathogenesis of stone formation. J Urol 1980;123:317.
9. Fleisch H. Inhibitors and promoters of stone formation. Kidney Int 1978;13:361.
10. Robertson WG, Peacock M, Marshall RW, Marshall EH, Nordin BEC. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med 1976;294:249.
11. Robertson WG, Peacock M, Nordin BEC. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1973;43:31.
12. Fellström B, Backman U, Danielson B, Wikström B. Treatment of renal calcium stone disease with the synthetic glycosaminoglycan pentosan polysulphate. World J Urol 1994;12:52.
13. Kok DJ, Papapoulos SE, Bijvoet OL. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 1990;37:51.
14. Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994;46:847.
15. Grases F, Costa-Bauzá A. Study of factors affecting calcium oxalate crystalline aggregation. Br J Urol 1990;66:240.
16. Brown CM, Purich DL. Physical chemical processes in kidney stone formation. In: Coe FL, Flavus MJ (eds): Disorders of Bone and Mineral Metabolism. New York: Raven Press, 1992, pp 613-624.
17. Suzuki K, Tsugawa R. Analysis of glycosaminoglycans induced in newly formed calcium oxalate crystals using an undiluted urine system. Scanning Microsc 1995;9:1089.
18. Nakatani T, Ishii K, Yoneda Y, et al. The preventive effect of sodium pentosan polysulfate against renal stone formation in hyperoxaluric rats. Urol Res 2002;30:329.
19. Boevé ER, Cao LC, Verkoelen CF, Romijin JC, de Bruijn WC, Schröder FH. Glycosaminoglycans and other sulphated polysaccharides in calculogenesis on urinary stones. World J Urol 1994;12:43.
20. Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine: Studies on their mode of action in artificial urine. J Urol 1986;136:128.
21. Caudarella R, Stefani F, Rizzoli E, Malavolta N, D'Antuona G. Preliminary results of glycosaminoglycan excretion in normal and stone-forming subjects: Relationship with uric acid excretion. J Urol 1983;129:665.
22. Grases F, Llompart I, Conte A, Coll R, March JG. Glycosaminoglycans and oxalocalcic urolithiasis. Nephron 1994;68:449.
23. Hwang TIS, Preminger GM, Poindexter J, Pak CYC. Urinary glycosaminoglycans in normal subjects and patients with stones. J Urol 1988;139:995.
24. Michelacci YM, Glashan RQ, Schor N. Urinary excretion of glycosaminoglycans in normal and stone forming subjects. Kidney Int 1989;36:1022.
25. Nesse A, Garbossa G, Romero MC, Bogado CE, Zanchetta JR. Glycosaminoglycans in urolithiasis. Nephron 1992;62:36.
26. Nikkilä MT. Urinary glycosaminoglycan excretion in normal and stone-forming subjects: significant disturbance in recurrent stone formers. Urol Int 1989;44:157.
27. Ryall RL, Marshall VR. The relationship between urinary inhibitory activity and endogenous concentrations of glycosaminoglycans and uric acid: Comparison of urine from stone-formers and normal subjects. Clin Chim Acta 1984;141:197.
28. Sallis JD, Lumley MF. On the possible role of glycosaminoglycans as natural inhibitors of calcium oxalate stones. Invest Urol 1979;16:296.
29. Hesse A, Wuzel H, Vahlensieck W. The excretion of glycosaminoglycans in the urine of calcium-oxalate-stone patients and healthy persons. Urol Int 1986;41:81.
30. Hess B, Nakagawa Y, Parks JH, Coe FL. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 1991;260:569.
31. Meyer JL. Nucleation kinetics in the calcium oxalate-sodium urate monohydrate system. Invest Urol 1981;19:197.
32. Kok DJ, Papapoulos SE, Blomen LJ, Bijvoet OL. Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 1988;34:346.
33. McGeown MG. Heredity in renal stone disease. Clin Sci 1960;19:465.
34. Menon M, Mahle CJ. Urinary citrate excretion in patients with renal calculi. J Urol 1983;129:1158.
35. Nicar MJ, Skurla C, Sakhaee K, Pak CY. Low urinary citrate excretion in nephrolithiasis. Urology 1983;21:8.
36. Schwille PO, Scholz D, Schwille K. Citrate in urine and serum and associated variables in subgroups of urolithiasis: Results from an outpatient stone clinic. Nephron 1982;31:194.
37. Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosan polysulphate: Comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980;19:455.
38. Faaij RA, Srivastava N, Van Griensven JMT, et al. The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. Eur J Clin Pharmacol 1999;54:929.
39. Fellström B, Danielson BG, Ljunghall S, et al. Crystal inhibition: The effects of polyanions on calcium oxalate crystal growth. Clin Chim Acta 1986;158:229.
40. Parsons CL, Schmidt JD, Pollen JJ. Successful treatment of interstitial cystitis with sodium pentosanpolysulfate. J Urol 1983;130:51.
41. Norman RW, Scurr DS, Robertson WG, Peacock M. Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate crystallization in vitro and in vivo. Clin Sci 1985;68:369.
42. Norman RW, Scurr DS, Robertson WG, Peacock M. Inhibition of calcium oxalate crystallization by pentosan polysulphate in control subjects and stone formers. Br J Urol 1984;56:594.
43. Parsons CL, Pollen JJ, Anwar H, Stauffer C, Schmidt JD. Antibacterial activity of bladder surface mucin duplicated in the rabbit bladder by exogenous glycosaminoglycan (sodium pentosanpoly-sulfate). Infect Immun 1980;27:876.
44. Subha K, Varalakshmi P. Alterations in some risk factors and urinary enzymes in urolithiatic rats treated with sodium pentosan polysulphate. Biochem Mol Biol Int 1993;29:271.
45. Zupkas P, Parsons CL, Percival C, Monga M. Pentosanpolysulfate coating of silicone reduces encrustation. J Endourol 2000;14:483.
46. Parsons CL, Danielson B, Feldstrom B. Inhibition of sodium urate crystal adherence to bladder surface by polysaccharide. J Urol 1985;134:614.